Loading
A blood test for leftover lymphoma that looks for several of the tumour's mutations sitting on the same piece of DNA, which lets it see far smaller traces than tests that look for one mutation at a time.
Foresight CLARITY is the commercial residual disease test of Foresight Diagnostics of Boulder, Colorado, built on PhasED-Seq (Phased Variant Enrichment and Detection Sequencing), the method published from Stanford by Kurtz and colleagues in 2021. The company's site describes Foresight Diagnostics as a wholly owned subsidiary of Natera and states that CLARITY has not been cleared or approved by the FDA.
Its analytical validation was in B-cell malignancies, chiefly diffuse large B-cell lymphoma (Klimova et al., Oncotarget 2025): a false positive rate of 0.24 per cent, a background error rate of 1.95 x 10^-8, and a 95 per cent detection limit of 0.7 parts per million with 120 ng of input DNA. Against a single-nucleotide-variant comparator, positive percent agreement was 90.62 per cent and negative percent agreement 77.78 per cent. The validation does not cover solid tumours.
Sequencing of the tumour finds stretches of DNA that carry two or more mutations on the same short fragment (phased variants); the blood test looks for fragments carrying those mutations together, which background sequencing errors almost never reproduce.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Reading several mutations on one fragment pushes detection below one part per million in lymphoma, where such clustered mutations are common. It has not been shown in breast cancer, where they are rarer.
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Query for this drug: (TITLE:"Foresight CLARITY" OR ABSTRACT:"Foresight CLARITY" OR TITLE:"CLARITY MRD" OR ABSTRACT:"CLARITY MRD" OR TITLE:"Foresight CLARITY MRD" OR ABSTRACT:"Foresight CLARITY MRD" OR TITLE:"PhasED-Seq MRD assay" OR ABSTRACT:"PhasED-Seq MRD assay") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Foresight CLARITY, not a curated reading list.
Shares Tumour-informed versus tumour-naive ctDNA assays, Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA) and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA) and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/